How Much Did Attralus Raise?
Funding & Key Investors

Attralus, a San Francisco-based biopharmaceutical innovator, has successfully secured significant capital to advance its mission in treating systemic amyloidosis. The company has reached a cumulative valuation milestone, with a total funding amount of $141M. This trajectory was bolstered by a recent strategic investment of $116M, which underscores the market confidence in the firm's proprietary therapeutic pipeline and its potential to address critical unmet medical needs in the rare disease space.

The funding history reflects a disciplined growth strategy, beginning with its initial Series A round in September 2020 and accelerating through a substantial Series B financing in September 2021. This capital infusion positions Attralus as a formidable player in the biotechnology sector, providing the necessary runway to transition from early-stage development to more advanced clinical milestones.

What is Attralus?

Attralus
ManufacturingPharmaceuticalsBusiness Services

Attralus is a specialized biopharmaceutical enterprise dedicated to the development of transformative medicines for systemic amyloidosis, a group of rare and serious diseases characterized by the accumulation of misfolded proteins. By leveraging a sophisticated platform designed to target and clear amyloid deposits, the company is positioned at the intersection of precision medicine and protein homeostasis. Its market position is defined by a commitment to scientific rigor and the pursuit of novel therapeutic modalities that aim to improve patient outcomes in conditions where current standard-of-care options remain limited. The company's focus on systemic amyloidosis places it within a high-growth niche of the biopharma industry, attracting institutional interest from firms specializing in long-term healthcare value creation.

How much funding has Attralus raised?

Attralus has raised a total of $141M across 2 funding rounds:

2020

Series A

$25M

2021

Series B

$116M

Series A (2020): $25M with participation from venBio Partners

Series B (2021): $116M led by Janus Henderson Investors, Redmile Group, Logos Capital, and Samsara BioCapital

Key Investors in Attralus

venBio Partners

A life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs.

Janus Henderson Investors

A global investment management firm providing a broad range of investment solutions and advisory services, focused on achieving strong long-term outcomes through disciplined research.

Redmile Group

A New York-based firm operating within the venture capital and private equity industry, known for its strategic focus on high-growth healthcare and biotechnology enterprises.

What's next for Attralus?

With the successful closure of its recent financing, Attralus is poised to accelerate its clinical development programs and expand its research capabilities. The strategic deployment of this capital will likely focus on advancing its lead candidates through human trials, optimizing manufacturing processes, and strengthening its intellectual property portfolio. As the company matures, the focus will shift toward demonstrating clinical efficacy and safety, which are essential precursors to potential regulatory filings and long-term commercialization. The backing from top-tier life sciences investors suggests a clear path toward scaling operations and potentially exploring strategic partnerships that could further validate its therapeutic platform in the global healthcare market.

See full Attralus company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Manufacturing industry

Food & BeverageManufacturing
Industrial Machinery & EquipmentManufacturingRetailFurniture
ManufacturingPlastic, Packaging & ContainersBuilding Materials
ManufacturingPlastic, Packaging & Containers

Frequently Asked Questions Regarding Attralus Financial Insights

What are the most recent funding rounds that Attralus has completed, and what were the funding rounds?
Attralus has recently completed 2 funding rounds: Series B on Sep 8, 2021, Series A on Sep 14, 2020.
What is the total amount of funding Attralus has raised to date?
Attralus has raised a total of $141M in funding to date.
How many funding rounds has Attralus completed?
Attralus has completed 2 funding rounds.
How much funding did Attralus raise in its most recent funding round?
Attralus raised $116M in its most recent funding round.
Who are the lead investors in Attralus's latest funding round?
The lead investor in Attralus's latest funding round was Janus Henderson Investors. To access investor data and explore similar companies, sign up for ZoomInfo.
Which was the largest funding round in Attralus's history?
The largest funding round in Attralus's history was $116M.
See more information about Attralus